Roche Holding AG (ROG.EB) said Monday that it entered a definitive merger agreement to acquire Philadelphia-based Spark Therapeutics Inc. ONCE. The Swiss pharmaceutical company said it would acquire Spark for $114.50 per share and that the deal is expected to close in the second quarter. Under the terms of the deal, Roche will file a tender offer to acquire all outstanding shares of Spark common stock, and Spark will file a recommendation statement containing the unanimous recommendation of the Spark board that its shareholders tender their shares to Roche.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Roche Nears Deal to Buy Spark Therapeutics for Close to $5 BillionRoche Holding AG is nearing a deal to buy Philadelphia biotech company Spark Therapeutics Inc., according to people familiar with the matter, as the Swiss drugmaker seeks to expand its presence treating hemophilia.
Weiterlesen »
Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy, which just became the priciest medicine in the USSwiss company Roche nearing a deal to buy Philadelphia-based biotech Spark Therapeutics, the WSJ reported Saturday. Spark's therapy for a rare form of blindness is the most expensive US medicine.
Weiterlesen »
How Warren’s child-care plan could spark pay raises for all school teachersSen. Elizabeth Warren’s child care program is, on the surface, a plan to substantially boost the availability of quality, affordable child care. But a look at the details, even before it’s turned into an actual bill, show that it would also have a massive impact on teacher pay across the country, and impact state and local government finances.
Weiterlesen »